Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum

Journal of Clinical Virology

Volumn 50, Issue 4, 2011, Pages 292-296

  Wursthorn, Karsten ^a   Jaroszewicz, Jerzy ^a,b   Zacher, Behrend J ^a   Darnedde, Martina ^a   Raupach, Regina ^a   Mederacke, Ingmar ^a   Cornberg, Markus ^a   Manns, Michael P ^a   Wedemeyer, Heiner ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Elecsys; HBsAg; Hepatitis B surface antigen; Quantification

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE;

ALGORITHM; ARTICLE; CLINICAL ARTICLE; ELECSYS HBSAG II ASSAY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; PRIORITY JOURNAL; VIRUS MUTANT; VIRUS MUTATION;

CLINICAL LABORATORY TECHNIQUES; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOASSAY; LAMIVUDINE; LONGITUDINAL STUDIES; MUTATION; NUCLEOSIDES; PYRIMIDINONES; REAGENT KITS, DIAGNOSTIC;

EID: 79952623084     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2010.12.008     Document Type: Article

References (27)

1. Lok A.S., McMahon B.J. AASLD guidelines. Chronic hepatitis B: update 2009. Hepatology 2009, 50:1-36.
2. European Association for the Study of the Liver EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009, 50:227-242.
3. Jaroszewicz J., Serrano B.C., Wursthorn K., Deterding K., Schlue J., Raupach R., et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010, 52:514-522.
4. Nguyen T., Thompson A.J., Bowden S., Croagh C., Bell S., Desmond P.V., et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010, 52:508-513.
5. Brunetto M.R., Moriconi F., Bonino F., Lau G.K.K., Farci P., Yurdaydin C., et al. Hepatitis B virus surface antigen levels - a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009, 49:1141-1150.
6. Sugiyama M., Tanaka Y., Kato T., Orito E., Ito K., Acharya S.K., et al. Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. Hepatology 2006, 44:915-924.
7. Wong G.L., Chan H.L. Predictors of treatment response in chronic hepatitis B. Drugs 2009, 69:2167-2177.
8. Manesis E.K., Hadziyannis E.S., Angelopoulou O.P., Hadziyannis S.J. Prediction of treatment related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007, 12:73-82.
9. Brunetto MR, Moriconi F, Bonino F, Lau GK, Piratvisuth T, Marcellin P, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49:1141-50.
10. Marcellin P., Brunetto M., Bonino F., Hadziyannis S.J., Kapprell H.-P., McCloud P.I., et al. In patients with HBeAg-negative chronic hepatitis B HBsAg serum levels early during treatment with peginterferon alfa-2a predict HBsAg clearance 4 years post-treatment. Hepatology 2008, 48(Suppl. 1):718A. [919].
11. Brunetto MR, Oliveri F, Colombatto P, Maina AM, Cavallone D, Bonino F, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology. 2010; 139:483-90.
12. Moucari R., Korevaar A., Lada O., Martinot-Peignoux M., Boyer N., Mackiewicz V., et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. Hepatology 2009, 49:1151-1157.
13. Wiegand J., Wedemeyer H., Finger A., Heidrich B., Rosenau J., Michel G., et al. A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative HBeAg or HBV DNA levels. Antivir Ther 2008, 13:547-554.
14. Wursthorn K, Jung M, Goodman ZD, Manns MP, Wedemeyer H, Naoumov NV, et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010; 52:1611-20.
15. Muhlbacher A., Weber B., Burgisser P., Eiras A., Cabrera J., Louisirirotchanakul S., et al. Multicenter study of a new fully automated HBsAg screening assay with enhanced sensitivity for the detection of HBV mutants. Med Microbiol Immunol 2008, 197:55-64.
16. Louisirirotchanakul S., Khupulsup K., Akraekthalin S., Chan K.P., Saw S., Aw T.C., et al. Comparison of the technical and clinical performance of the Elecsys® HBsAg II assay with the Architect®, AxSym® and Advia® Centaur HBsAg screening assays. J Med Virol 2010, 82:755-762.
17. Bonino F., Ofenloch B., Melchior W., Upmeier B., Rößler D., van der Helm W. Quantitative assessment of serum HBsAg levels using the Elecsys® HBsAg II screening assay: results of a feasibility study. 59th annual meeting of the American association for the study of liver diseases 2008:Poster P934 2008
18. Lai C.L., Gane E., Liaw Y.F., Hsu C.W., Thongsawat S., Wang Y., et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007, 357:2576-2588.
19. Liaw Y.F., Gane E., Leung N., Zeuzem S., Wang Y., Lai C.L., et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009, 136:486-495.
20. Hsu C.-W., Chen Y.-C., Liaw Y.-F., Gane E., Manns M., Zeuzem S., et al. Prolonged efficacy and safety of 3 years of continuous telbivudine treatment in pooled data from GLOBE and 015 studies in chronic hepatitis B patients. J Hepatol 2009, 50(Suppl. 1):S331. [991].
21. Jia JD, Hong M, Wei L, Gao ZL, Hou JL, Zhang J, et al. Multicentre evaluation of the Elecsys hepatitis B surface antigen II assay for detection of HBsAg in comparison with other commercially available assays. Med Microbiol Immunol. 2009 Nov; 198 (4): 263-9.
22. Ly T.D., Servant-Delmas A., Bagot S., Gonzalo S., Férey M.P., Ebel A., et al. Sensitivities of four new commercial hepatitis B virus surface antigen (HBsAg) assays in detection of HBsAg mutant forms. J Clin Microbiol 2006, 44:2321-2326.
23. Weber B., Dengler T., Berger A., Doerr H.W., Rabenau H. Evaluation of two new automated assays for hepatitis B virus surface antigen (HBsAg) detection: IMMULITE HBsAg and IMMULITE 2000 HBsAg. J Clin Microbiol 2003, 41:135-143.
24. Weber B. Recent developments in the diagnosis and monitoring of HBV infection and role of the genetic variability of the S gene. Expert Rev Mol Diagn 2005, 5:75-91.
25. Akarsu M., Sengonul A., Tankurt E., Sayiner A.A., Topalak O., Akpinar H., et al. YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay. J Gastroenterol Hepatol 2006, 21:1783-1788.
26. Kobayashi S., Ide T., Sata M. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol 2001, 34:584-586.
27. Kirishima T., Okanoue T., Daimon Y., Itoh Y., Nakamura H., Morita A., et al. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol 2002, 37:259-265.